Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system,
has emerged as an attractive novel cancer chemotherapeutic modality. Although …

As the ubiquitin–proteasome system (UPS) regulates almost every biological process, the
dysregulation or aberrant expression of the UPS components causes many pathological …

Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its
function is crucial to cellular homeostasis. First synthesized as probes of proteolytic …

Background: The ubiquitin-proteasome system has become a promising novel molecular
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …

The ubiquitin-proteasome pathway (UPP) is the major non-lysosomal proteolytic system in
the cytosol and nucleus of all eukaryotic cells. Bortezomib (also known as PS-341 and …

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been
proven to be a promising target for cancer therapy. Bortezomib is the first US Food and Drug …